Pancreatic Cancer Resectable Clinical Trial
Official title:
Study on the Efficacy and Safety of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
The study is a multicenter, prospective clinical study aimed at evaluating the efficacy and safety of Huaier Granule in postoperative adjuvant treatment of resectable pancreatic cancer
The study is a multicenter, prospective clinical study, expected to include subjects who visited the selected research center from April 2024 to March 2026, underwent radical tumor resection surgery, and were pathologically diagnosed with pancreatic adenocarcinoma. The subjects are divided into two groups. One group is the standard chemotherapy group, with a planned inclusion of no less than 428 subjects. The chemotherapy will be treated using the Class 1A chemotherapy regimen recommended by the 2022 version of the CSCO guidelines; One group is the Huaier treatment group, with a planned inclusion of no less than 214 subjects. All subjects voluntarily give up the postoperative adjuvant treatment recommended by the guidelines and only choose Huaier granules for postoperative adjuvant treatment. A total of no less than 642 subjects are planned to be included. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06375928 -
EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial)
|
N/A | |
| Recruiting |
NCT06388967 -
Pancreatic Cancer Detection Consortium
|
||
| Completed |
NCT05483257 -
Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
|
||
| Recruiting |
NCT05287165 -
Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms
|
Early Phase 1 | |
| Not yet recruiting |
NCT06287749 -
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
|
||
| Recruiting |
NCT03977233 -
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04736043 -
Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Resected Pancreatic Cancer Using Organoid
|
||
| Completed |
NCT04224402 -
Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.
|
Phase 2 | |
| Terminated |
NCT03344172 -
Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05479708 -
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
|
||
| Not yet recruiting |
NCT05637567 -
Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head
|
Phase 2 | |
| Recruiting |
NCT05181605 -
Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors
|
Phase 2/Phase 3 |